10-K: Bluejay Diagnostics Faces Going Concern Amidst Funding Crisis

Bluejay Diagnostics reported significant losses, a going concern warning, and critical funding needs to advance its Symphony platform and FDA submission.

Summary

• The company has incurred significant losses since its inception, with a net loss of approximately $6.8 million in 2025 and $7.7 million in 2024.
• An accumulated deficit of approximately $41.5 million was reported as of December 31, 2025.
• Cash and cash equivalents stood at $5.2 million as of December 31, 2025, against current liabilities of $1.1 million.
• Management estimates current cash resources will only be sufficient to fund operations until the third quarter of 2026.
• At least $20 million in additional capital is required by the end of fiscal year 2027 to finance operations and commercialization efforts.
• The company is developing the Symphony IL-6 test for sepsis, with a goal to submit a 510(k) regulatory application to the FDA in 2027 and achieve clearance thereafter.
• Patient enrollment for the SYMON-II pivotal clinical trial is ongoing, with approximately 583 out of a target of 750 patients enrolled as of March 2, 2026.
• Manufacturing issues with the Symphony cartridges, produced by Sanyoseiko, need to be resolved before clinical trial samples can be tested, causing delays.
• The market price of the company's common stock has fallen by over 99.9% since its IPO in November 2021, and it has undergone multiple reverse stock splits (1-for-32,000 aggregate since July 2023).
• Nasdaq listing is at risk due to potential failure to meet the minimum bid price ($1.00) and a proposed new $5 million market value of listed securities requirement.
• Intellectual property for the Symphony cartridges is exclusively licensed from Toray, with key patents expiring between 2027 and 2030, creating a narrow window for commercialization under patent protection.
• The President and CEO, Neil Dey, also serves as the principal financial and accounting officer, and the company has only 6 full-time employees, raising concerns about internal controls and operational capacity.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as highly negative due to the explicit 'going concern' warning, critical funding needs far exceeding current market capitalization, severe stock price depreciation, imminent Nasdaq delisting risk, and significant delays in core product development and regulatory timelines.

Positives

• Completed the pre-clinical development of the Symphony analyzer.
• Successfully transferred the knowledge, technology, and process for Symphony cartridge production from Toray Industries to Sanyoseiko, an FDA-certified contract manufacturing facility.
• The SYMON-I pilot clinical study suggested that IL-6 levels may predict 28-day all-cause mortality in sepsis patients, highlighting the potential clinical utility of the Symphony IL-6 test.
• The SYMON-II pivotal clinical study is actively enrolling patients, with 583 out of a target of 750 patients already collected, frozen, and biobanked.
• There are currently no FDA-cleared or approved IL-6 tests on the market, potentially offering a significant competitive advantage if the Symphony IL-6 test receives regulatory clearance.
• The Symphony platform is designed to provide rapid, laboratory-quality results in approximately 20 minutes in critical care settings, addressing a significant market need.
• An exploratory strategic initiative is underway to evaluate the integration of artificial intelligence (AI) capabilities into the Symphony platform to enhance biomarker data interpretation and sepsis risk stratification.
• A shareholder complaint filed in New Jersey Civil Court was resolved for a reimbursement of $1,050 in out-of-pocket expenses, avoiding further costly litigation.

Negatives

• The company reported a net loss of approximately $6.8 million for the year ended December 31, 2025, and an accumulated deficit of $41.5 million, indicating a history of unprofitability.
• Negative cash flow from operating activities amounted to approximately $6.1 million in 2025 and $7.8 million in 2024.
• Current cash and cash equivalents are projected to be sufficient only until the third quarter of 2026, raising substantial doubt about the company's ability to continue as a going concern.
• At least $20 million in additional capital is required by the end of fiscal year 2027, an amount several times greater than the current market capitalization, which will likely result in significant shareholder dilution.
• The market price of common stock has fallen by over 99.9% since its November 2021 IPO, and the company has undergone multiple reverse stock splits (1-for-32,000 aggregate since July 2023) to maintain Nasdaq listing.
• The company's Nasdaq listing is at risk due to the minimum bid price requirement ($1.00) and a recently proposed $5 million market value of listed securities requirement, which it currently does not meet.
• The number of shares underlying outstanding warrants is several times greater than currently outstanding common stock, posing a significant risk of future dilution and potential downward pressure on the stock price.
• Critical manufacturing issues with the Symphony cartridges need to be resolved, delaying the testing of SYMON-II clinical trial samples and the overall FDA submission timeline.
• The intellectual property licensed from Toray for the Symphony cartridges has patents expiring between 2027 and 2030, creating a narrow window for commercialization under patent protection.
• The company downsized its full-time employee headcount to 6 persons in 2025 to conserve cash, which may negatively impact business continuity and product development timelines.
• The President and CEO also serves as the principal financial and accounting officer, and there are no full-time employees devoted to finance, accounting, legal, or compliance functions, increasing the likelihood of internal control failures.
• Limited authorized shares remaining under equity compensation plans hinder the ability to incentivize directors and employees with non-cash compensation, leading to substantial cash compensation obligations relative to market capitalization.
• There are no current revenue-generating operations, and the company expects to continue incurring significant operating losses for the foreseeable future.
• There is a risk that the validation of the primary outcome measure of the SYMON-I study will not achieve statistical significance in the SYMON-II trial.
• The cartridges, a core component of the Symphony system, may not pass analytical validation.
• The SEC's 'baby shelf rules' limit the company's ability to raise capital via its Form S-3 shelf registration statement to approximately $700,000 in the near-term, restricting financing options.
• The company identified material weaknesses in internal control over financial reporting in connection with its 2024 Annual Report on Form 10-K.

Risks

• The company has incurred significant losses since inception, does not currently generate any operating income, and may never achieve or maintain profitability.
• Additional funding is required to finance operations and continue as a going concern, which may not be available on acceptable terms, or at all, potentially leading to liquidation.
• The market price of common stock has fallen by over 99.9% since the IPO, and future funding may result in substantial dilution and further declines in trading price.
• The large number of shares underlying outstanding warrants could negatively affect the market price of common stock and make future equity offerings more difficult.
• The company's common stock may be delisted from the Nasdaq Capital Market if it fails to meet listing requirements, including minimum bid price and market value of listed securities.
• License arrangements with Toray are subject to risks, including potential termination if the company fails to establish an alternative cartridge manufacturing site by October 2026.
• Certain manufacturing processes have caused prior performance and reproducibility issues with the Symphony cartridges, delaying clinical trial sample testing.
• The Symphony platform, including its software and systems, may contain undetected errors, limiting product provision and diminishing attractiveness.
• Failure to comply with regulatory quality system regulations could interrupt proposed operations and negatively impact operating results.
• Violation of laws protecting patient health information confidentiality could lead to civil or criminal penalties and harm reputation.
• Significant raw material shortages, supplier capacity constraints, disruptions, and sourcing issues may adversely impact product sales and margins.
• The regulatory clearance process is expensive, time-consuming, and uncertain, potentially preventing clearance for planned products.
• Future clinical data may not meet required objectives, delaying, limiting, or preventing regulatory clearance.
• Inability to complete required clinical evaluations or significant delays could prevent or significantly delay the targeted product launch timeframe.
• Failure by the company or its suppliers to meet regulatory quality standards applicable to manufacturing processes could have an adverse effect on the business.
• The company may be liable if the FDA or another regulatory agency concludes it engaged in off-label promotion of its products.
• Legislative or regulatory reforms may make it more difficult and costly to obtain regulatory clearance or approval and to manufacture, market, and distribute products.
• Dependence on intellectual property licensed from Toray, with any dispute over the license significantly harming the business.
• Reliance primarily on Toray to file, prosecute, maintain, defend, and enforce intellectual property material to the business.
• Inability of the company and/or Toray to protect or enforce licensed intellectual property rights could impair competitive position.
• The company and/or Toray may be subject to claims alleging the violation of intellectual property rights of others.
• The company and Toray may be subject to claims challenging the invention of the intellectual property licensed from Toray.
• Analytical validation, required for FDA clearance, may take longer than expected.
• The FDA could request additional data or testing after application submission, requiring additional costs and delaying approval.
• Intense competition in the diagnostic testing market, particularly in the IL-6 space, may prevent effective competition.
• Sales of substantial amounts of securities in the public market could depress the market price of common stock.
• Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on the business and stock price.
• Limited internal staffing, with the President and CEO serving as principal financial and accounting officer and no full-time finance, accounting, legal, or compliance functions, may increase the likelihood of internal control failures.
• Downsizing the organization in 2025 to preserve cash resources may reduce business continuity and affect product development and timelines.
• The company is subject to risks associated with new businesses, including a limited operating history and inability to generate sustainable revenue.
• Failure to demonstrate that collected clinical samples do not degrade over time could require a redesign of the business plan.
• There is a risk that validation of the primary outcome measure of the SYMON-I study will not achieve statistical significance.
• If third-party payors do not provide coverage and reimbursement for the use of the platform, the business and prospects may be negatively impacted.
• The Symphony platform, including its software and systems, may contain undetected errors, limiting product provision and diminishing attractiveness.
• Reliance on the proper function, security, and availability of information technology systems and data, with a risk of breaches, cyber-attacks, or other disruptions.
• Inability to attract and retain highly skilled managerial, scientific, and technical personnel.
• Product liability suits, whether or not meritorious, could be brought against the company.
• Healthcare legislative reform measures could have a material adverse effect on the business, future revenue, and results of operations.
• Products may be subject to recalls after receiving FDA or foreign approval or clearance.
• Legislative or regulatory reforms may make it more difficult and costly to obtain regulatory clearance or approval of future products.
• If the company or Toray fail to respond quickly to technological developments, products may become uncompetitive and obsolete.
• The company could issue blank check preferred stock without stockholder approval, diluting interests and impairing voting rights.
• Anti-takeover provisions in charter documents and Delaware law could discourage a takeover.
• The company will continue incurring increased costs as a result of operating as a public company, and management must devote substantial time to new compliance initiatives.
• As an emerging growth company, the company is subject to lessened disclosure requirements, which could leave stockholders without information or rights available to stockholders of other public companies.
• The company's election to use the extended transition period for complying with new or revised accounting standards may make its financial statements not comparable to companies that comply with public company effective dates.
• An exclusive forum provision in the charter documents could limit stockholders' ability to obtain a favorable judicial forum for disputes.

Future Outlook

The company expects to continue incurring significant operating losses in 2026 and 2027 and will require at least $20 million in additional capital by the end of fiscal year 2027. It aims to complete patient enrollment for the SYMON-II study in summer 2026, resolve cartridge manufacturing issues and verify cartridges during 2026, and begin testing samples by the end of 2026. The goal is to submit a 510(k) regulatory application to the FDA in 2027, with an objective of achieving FDA clearance thereafter. The company also hopes to develop additional tests for the Symphony platform and explore strategic opportunities around its IL-6 intellectual property and biobanks, including an exploratory initiative to integrate AI capabilities. Stockholder approval will be sought in 2026 to reload shares for equity incentive plans.

Management Comments

• "We expect to need to raise at least $20 million of further capital by the end of the 2027 fiscal year, which we hope to do in various tranches."
• "Our goal is to produce and verify these cartridges during 2026 and be in position to analyze the blood samples using our Symphony IL-6 test in the third quarter of 2026, with a goal of being in position to submit a 510(k) regulatory application to the FDA in 2027 and an objective of achieving FDA clearance thereafter."
• "We believe that the findings underscore the potential importance of IL-6 as a predictor and provide new insights into the potential pathways for improving sepsis outcomes."
• "Our goal is to become the first provider of rapid tests for critical care settings, including infectious, inflammatory and metabolic diseases, by leveraging the strengths of our Symphony platform."
• "We expect to monitor and continue to reduce our general and administrative spend, as necessary, to optimize operational alignment."
• "The Company believes that the complaint was without merit and included several allegations that were directly contradicted by the Companys public filings and were not based in fact."
• "To conserve costs, our President and Chief Executive Officer serves as our principal financial and accounting officer, in addition to being our principal executive officer."

Industry Context

StockSavvy.ai notes that Bluejay Diagnostics operates in the highly competitive in vitro diagnostics (IVDs) market, specifically targeting critical care settings for sepsis. The company aims to differentiate itself with its rapid, near-patient Symphony IL-6 test, which currently has no direct FDA-cleared or approved competitors for general IL-6 measurement, though some EUA-granted tests exist for COVID-19. The market is dominated by large medical device companies with significant R&D and market control, posing a substantial challenge for Bluejay, an early-stage company with no revenue. The focus on IL-6 as a sepsis biomarker aligns with industry trends seeking faster, more accurate diagnostic tools for critical conditions. The exploration of AI integration suggests an awareness of evolving technological advancements in diagnostics.

Comparison to Industry Standards

• There are currently no FDA cleared or approved IL-6 tests on the market, which could provide Bluejay Diagnostics with a first-mover advantage if its Symphony IL-6 test receives clearance.
• Existing IL-6 tests granted under FDA Emergency Use Authorization (EUA) for COVID-19 patients, such as Roche Cobas, Siemens ADVIA Centaur, and Beckman Coulter Access 2, are central laboratory size equipment and require pre-processing of whole blood.
• Bluejay's Symphony platform is designed for near-patient use and can handle various liquid sample types, including whole blood, which the company believes provides a substantial competitive advantage over existing central lab solutions.

Management Changes

Corporate Governance

Legal Proceedings

• A shareholder complaint was filed on December 8, 2025, in New Jersey Civil Court alleging negligent misrepresentation, misrepresentation, and consumer deception against the company and its former CFO, Kenneth Fisher, seeking $20,000 in damages.
• The company filed an answer and counterclaim for defamation on January 20, 2026.
• The matter was dismissed on February 17, 2026, after the company accepted an offer for a mutual release of claims, reimbursing the plaintiff $1,050 for out-of-pocket expenses.

Related Party Transactions

• The company had a Sharing and Services Agreement with NanoHybrids, Inc. (where former CTO Jason Cook was CEO and majority shareholder) in December 2021, billing for R&D staff, lab facility use, and rebilling lab supplies. Income from NanoHybrids was $6,873 in 2025 and $127,079 in 2024.
• President and CEO Neil Dey and his spouse (also a director) serve as officers and/or directors of Laminar Pharma, Inc., an unaffiliated business permitted to use the company's main facility as its registered business address.

Stakeholder Impact

• Shareholders face significant dilution risk from future capital raises, substantial decline in stock price (over 99.9% since IPO), risk of Nasdaq delisting, and potential for little to no return if the company liquidates.
• Employees have been impacted by downsizing to 6 full-time employees to conserve cash, with potential for further reductions and limited non-cash compensation incentives.
• Future customers may benefit from a rapid, near-patient sepsis diagnostic test if approved, but ongoing delays in development and regulatory clearance could impact product availability.
• Suppliers and Contract Manufacturing Organizations (CMOs), such as Sanyoseiko and Toray, are critical to the company's operations, with risks including potential license termination with Toray if manufacturing site establishment deadlines are not met.
• Creditors face increased risk due to the explicit 'going concern' warning and the company's precarious financial position, raising concerns about its ability to meet future obligations.

Next Steps

• Complete patient enrollment in the SYMON-II pivotal clinical study in the summer of 2026.
• Produce and verify Symphony cartridges during 2026 to meet FDA requirements for submission and commercial production.
• Analyze biobanked blood samples using the Symphony IL-6 test in the third quarter of 2026.
• Submit a 510(k) regulatory application to the FDA in 2027.
• Achieve FDA clearance for the Symphony IL-6 test thereafter.
• Raise at least $20 million in additional capital by the end of fiscal year 2027.
• Establish an alternative cartridge manufacturing site by October 23, 2026.
• Seek stockholder approval at the 2026 annual meeting to reload shares available under equity incentive plans.
• Present SYMON-I and SYMON-II results at future national scientific meetings and publish them in peer-reviewed journals, subject to positive outcomes.
• Explore new products for Symphony, including tests for myocardial infarction and congestive heart failure, and other biomarker detection programs.
• Explore strategic opportunities around pending IP on clinical utilities of IL-6 and specimen biobanks.
• Continue the exploratory initiative to evaluate the potential integration of artificial intelligence (AI) capabilities into the Symphony platform.

Key Dates

Recommendation

The company faces an existential threat with an explicit 'going concern' warning from its auditors and management's own admission that current cash will only last until Q3 2026. The need to raise at least $20 million by the end of 2027, an amount 'several times' its current market capitalization, indicates extreme dilution for existing shareholders. The stock has already plummeted over 99.9% since its IPO and faces imminent Nasdaq delisting. Critical manufacturing issues and regulatory delays further compound the uncertainty of its core product's commercialization. These factors present an exceptionally high-risk profile with a very low probability of a favorable outcome for investors.

Keywords

Sepsis diagnostics, IL-6 test, Medical devices, In vitro diagnostics, Critical care, FDA clearance, Symphony platform, Clinical trials, Going concern, Capital raise, Nasdaq delisting, Intellectual property, Contract manufacturing, Biotechnology, Healthcare technology